Thiazolidinediones as antidiabetic agents: A critical review

Global and societal implications of the diabetes epidemic

Zimmet, P., Alberti, K. G. M. M., & Shaw, J. (2001) · Nature · doi:10.1038/414782a · Cited by 5,883 · see citing works

Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators

Issemann, I., & Green, S. (1990) · Nature · doi:10.1038/347645a0 · Cited by 3,519 · see citing works

Ligand binding and co-activator assembly of the peroxisome proliferator-activated receptor-γ

Nolte, R. T., Wisely, G. B., Westin, S. K., Cobb, J. E., Lambert, M. H., Kurokawa, R., Rosenfeld, M. G., Willson, T. M., Glass, C. K., & Milburn, M. V. (1998) · Nature · doi:10.1038/25931 · Cited by 1,955 · see citing works

The Many Faces of PPARγ

Lehrke, M., & Lazar, M. A. (2005) · Cell · doi:10.1016/j.cell.2005.11.026 · Cited by 1,452 · see citing works

Control of the peroxisomal β-oxidation pathway by a novel family of nuclear hormone receptors

Dreyer, C., Krey, G. D., Keller, H., Givel, F., Helftenbein, G., & Wahli, W. (1992) · Cell · doi:10.1016/0092-8674(92)90031-7 · Cited by 1,373 · see citing works

PPARγ Mediates High-Fat Diet–Induced Adipocyte Hypertrophy and Insulin Resistance

Kubota, N., Terauchi, Y., Miki, H., Tamemoto, H., Yamauchi, T., Komeda, K., Satoh, S., Nakano, R., Ishii, C., 杉山, 拓., et al. (1999) · Molecular Cell · doi:10.1016/s1097-2765(00)80210-5 · Cited by 1,342 · see citing works

Adipose-specific peroxisome proliferator-activated receptor γ knockout causes insulin resistance in fat and liver but not in muscle

He, W., Barak, Y., Hevener, A. L., Olson, P., Liao, D., Le, J., Nelson, M. C., Ong, E. S., Olefsky, J. M., & Evans, R. M. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2536828100 · Cited by 978 · see citing works

Thiazolidinediones and the promise of insulin sensitization in type 2 diabetes

Soccio, R. E., Chen, E. R., & Lazar, M. A. (2014) · Cell Metabolism · doi:10.1016/j.cmet.2014.08.005 · Cited by 518 · see citing works

Recent developments and biological activities of thiazolidinone derivatives: A review

Jain, A. K., Vaidya, A., Ravichandran, V., Kashaw, S. K., & Agrawal, R. K. (2012) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2012.03.069 · Cited by 466 · see citing works

Lessons from the glitazones: a story of drug development

Gale, E. A. (2001) · The Lancet · doi:10.1016/s0140-6736(00)04960-6 · Cited by 289 · see citing works

Synthesis and aldose reductase inhibitory activity of 5-arylidene-2,4-thiazolidinediones

Bruno, G., Costantino, L., Curinga, C., et al. (2002) · Bioorganic & Medicinal Chemistry · doi:10.1016/s0968-0896(01)00366-2 · Cited by 252 · see citing works

Fibrates, Glitazones, and Peroxisome Proliferator–Activated Receptors

Lalloyer, F., & Staels, B. (2010) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.108.179689 · Cited by 217 · see citing works

Effect of Thiazolidinediones on Albuminuria and Proteinuria in Diabetes: A Meta-analysis

Sarafidis, P. A., Stafylas, P. C., Georgianos, P. I., Saratzis, A. N., & Lasaridis, A. N. (2010) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2009.11.013 · Cited by 197 · see citing works

PPARα and PPARγ dual agonists for the treatment of type 2 diabetes and the metabolic syndrome

Fiévet, C., Fruchart, J., & Staels, B. (2006) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2006.06.009 · Cited by 182 · see citing works

Molecular design, synthesis, and hypoglycemic and hypolipidemic activities of novel pyrimidine derivatives having thiazolidinedione

Lee, H., Kim, B. C., Ahn, J. B., et al. (2005) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2005.03.019 · Cited by 179 · see citing works

Studies on antidiabetic agents. II. Synthesis of 5-(4-(1-methylcyclohexylmethoxy)-benzyl)thiazolidine-2,4-dione (ADD-3878) and its derivatives.

Sohda, T., MIZUNO, K., Imamiya, E., Sugiyama, Y., Fujita, T., & KAWAMATSU, Y. (1982) · Chemical and Pharmaceutical Bulletin · doi:10.1248/cpb.30.3580 · Cited by 171 · see citing works

Effects of the New Dual PPARα/δ Agonist GFT505 on Lipid and Glucose Homeostasis in Abdominally Obese Patients With Combined Dyslipidemia or Impaired Glucose Metabolism

Cariou, B., Zaïr, Y., Staels, B., & Bruckert, É. (2011) · Diabetes Care · doi:10.2337/dc11-0093 · Cited by 171 · see citing works

Minireview: Challenges and Opportunities in Development of PPAR Agonists

Wright, M. B., Bortolini, M., Tadayyon, M., & Bopst, M. (2014) · Molecular Endocrinology · doi:10.1210/me.2013-1427 · Cited by 169 · see citing works

Synthesis and biological activity of novel substituted pyridines and purines containing 2,4-thiazolidinedione

Kim, B. Y., Ahn, J. B., Lee, H. W., et al. (2004) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2004.03.001 · Cited by 162 · see citing works

Free Fatty Acid Receptors FFAR1 and GPR120 as Novel Therapeutic Targets for Metabolic Disorders

Hara, T., Hirasawa, A., Ichimura, A., Kimura, I., & Tsujimoto, G. (2011) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.22639 · Cited by 156 · see citing works

Regulatory Action on Rosiglitazone by the U.S. Food and Drug Administration

Woodcock, J., Sharfstein, J. M., & Hamburg, M. A. (2010) · New England Journal of Medicine · doi:10.1056/nejmp1010788 · Cited by 146 · see citing works

Revisiting the Rosiglitazone Story — Lessons Learned

Rosen, C. J. (2010) · New England Journal of Medicine · doi:10.1056/nejmp1008233 · Cited by 123 · see citing works

Structure–activity relationships and molecular modelling of 5-arylidene-2,4-thiazolidinediones active as aldose reductase inhibitors

Maccari, R., Ottanà, R., Curinga, C., et al. (2005) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2005.02.026 · Cited by 120 · see citing works

Therapeutic journey of 2,4-thiazolidinediones as a versatile scaffold: An insight into structure activity relationship

Naim, M. J., Alam, M. J., Ahmad, S., Nawaz, F., Shrivastava, N., Sahu, M., & Alam, O. (2017) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2017.02.031 · Cited by 119 · see citing works

Identification of 5-arylidene-4-thiazolidinone derivatives endowed with dual activity as aldose reductase inhibitors and antioxidant agents for the treatment of diabetic complications

Ottanà, R., Maccari, R., Giglio, M., CORSO, A. D., Cappiello, M., Mura, U., Cosconati, S., Marinelli, L., Novellino, E., Sartini, S., et al. (2011) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2011.03.068 · Cited by 114 · see citing works

5-Arylidene-2,4-thiazolidinediones as inhibitors of protein tyrosine phosphatases

Maccari, R., Paoli, P., Ottanà, R., Jacomelli, M., Ciurleo, R., Manao, G., Steindl, T. M., Langer, T., Vigorita, M. G., & Camici, G. (2007) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2007.05.027 · Cited by 113 · see citing works

Synthesis, hypoglycemic and hypolipidemic activities of novel thiazolidinedione derivatives containing thiazole/triazole/oxadiazole ring

Iqbal, A. K. M., Khan, A. Y., Kalashetti, M. B., et al. (2012) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2012.04.015 · Cited by 111 · see citing works

Synthesis and activity of small molecule GPR40 agonists

Garrido, D. M., Corbett, D. F., Dwornik, K. A., Goetz, A. S., Littleton, T. R., McKeown, S. C., Mills, W. Y., Smalley, T. L. J., Briscoe, C. P., & Peat, A. J. (2006) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2006.01.007 · Cited by 111 · see citing works

The next generation of PPAR drugs: Do we have the tools to find them?

SHEARER, B. G., & Billin, A. N. (2007) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2007.05.005 · Cited by 106 · see citing works

Thiazolidinedione derivatives as PTP1B inhibitors with antihyperglycemic and antiobesity effects

Bhattarai, B. R., Kafle, B., Hwang, J., et al. (2009) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2009.09.020 · Cited by 94 · see citing works

Mechanisms by which Thiazolidinediones Enhance Insulin Action

Reginato, M. J., & Lazar, M. A. (1999) · Trends in Endocrinology and Metabolism · doi:10.1016/s1043-2760(98)00110-6 · Cited by 93 · see citing works

Novel thiazolidinedione derivatives with anti-obesity effects: Dual action as PTP1B inhibitors and PPAR-γ activators

Bhattarai, B. R., Kafle, B., Hwang, J., et al. (2010) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2010.08.130 · Cited by 91 · see citing works

The rise and fall of rosiglitazone

Nissen, S. E. (2010) · European Heart Journal · doi:10.1093/eurheartj/ehq016 · Cited by 90 · see citing works

Thiazolidinediones and PPAR orchestra as antidiabetic agents: From past to present

Yasmin, S., & Jayaprakash, V. (2016) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2016.12.020 · Cited by 90 · see citing works

Peroxisome Proliferators‐Activated Receptor (PPAR) Modulators and Metabolic Disorders

Cho, M.-C., Lee, K., Paik, S., & Yoon, D. (2008) · PPAR Research · doi:10.1155/2008/679137 · Cited by 89 · see citing works

Novel phthalazinone and benzoxazinone containing thiazolidinediones as antidiabetic and hypolipidemic agents

Madhavan, G. R., Chakrabarti, R., Kumar, S. K. B., et al. (2001) · European Journal of Medicinal Chemistry · doi:10.1016/s0223-5234(01)01257-0 · Cited by 88 · see citing works

5-Arylidene-2-phenylimino-4-thiazolidinones as PTP1B and LMW-PTP inhibitors

Ottanà, R., Maccari, R., Ciurleo, R., Paoli, P., Jacomelli, M., Manao, G., Camici, G., Laggner, C., & Langer, T. (2009) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2009.01.044 · Cited by 88 · see citing works

Targeting Peroxisome Proliferator-Activated Receptors Using Thiazolidinediones: Strategy for Design of Novel Antidiabetic Drugs

Thangavel, N., Bratty, M. A., Javed, S. A., Ahsan, W., & Alhazmi, H. A. (2017) · International Journal of Medicinal Chemistry · doi:10.1155/2017/1069718 · Cited by 88 · see citing works

Anti-apoptotic Actions of PPAR-γ Against Ischemic Stroke

Fong, W.-H., Tsai, H., Chen, Y.-C., Wu, J., & Lin, T. (2010) · Molecular Neurobiology · doi:10.1007/s12035-010-8103-y · Cited by 87 · see citing works

Synthesis and pharmacological evaluation of substituted 5-[4-[2-(6,7-dimethyl-1,2,3,4-tetrahydro-2-oxo-4-quinoxalinyl)ethoxy]phenyl]methylene]thiazolidine-2,4-dione derivatives as potent euglycemic and hypolipidemic agents

Gupta, D., Ghosh, N. N., & Chandra, R. (2005) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2004.12.041 · Cited by 84 · see citing works

Neuroprotective effects of pioglitazone in a rat model of permanent focal cerebral ischemia are associated with peroxisome proliferator-activated receptor gamma-mediated suppression of nuclear factor-κB signaling pathway

Zhang, H.-L., Xu, M., Wei, C., Qin, A.-P., Liu, C.-F., Hong, L.-Z., Zhao, X., Liu, J., & Qin, Z. (2010) · Neuroscience · doi:10.1016/j.neuroscience.2010.12.029 · Cited by 83 · see citing works

Saroglitazar for the treatment of dyslipidemia in diabetic patients

Joshi, S. (2015) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2015.1009894 · Cited by 80 · see citing works

Design, synthesis, in silico molecular docking and biological evaluation of novel oxadiazole based thiazolidine-2,4-diones bis-heterocycles as PPAR-γ agonists

Nazreen, S., Alam, M. S., Alam, M. S., et al. (2014) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2014.09.010 · Cited by 79 · see citing works

Synthesis, biological evaluation and molecular modeling studies of some novel thiazolidinediones with triazole ring

Chinthala, Y., Domatti, A. K., Alam, S., et al. (2013) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2013.10.005 · Cited by 75 · see citing works

Synthetic and natural Peroxisome Proliferator-Activated Receptor (PPAR) agonists as candidates for the therapy of the metabolic syndrome

Tan, C. K., Zhuang, Y., & Wahli, W. (2017) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2017.1280467 · Cited by 70 · see citing works

Design, synthesis, and biological evaluation of novel thiazolidinediones as PPARγ/FFAR1 dual agonists

Darwish, K. M., Salama, I., Mostafa, S. M., Gomaa, M. S., & Helal, M. A. (2015) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2015.12.049 · Cited by 67 · see citing works

In vitro aldose reductase inhibitory activity of 5-benzyl-2,4-thiazolidinediones

Rakowitz, D., Maccari, R., Ottanà, R., et al. (2005) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2005.08.056 · Cited by 65 · see citing works

Synthesis, biological evaluation and molecular modeling studies of arylidene-thiazolidinediones with potential hypoglycemic and hypolipidemic activities

Leite, L. F. C. D. C., Mourão, R. H. V., de Lima, M. D. C. A., et al. (2007) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2007.02.015 · Cited by 64 · see citing works

Thiazolidine-2,4-diones derivatives as PPAR-γ agonists: Synthesis, molecular docking, in vitro and in vivo antidiabetic activity with hepatotoxicity risk evaluation and effect on PPAR-γ gene expression

Nazreen, S., Alam, M. S., Alam, M. S., et al. (2014) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2014.05.034 · Cited by 60 · see citing works

Synthesis and biological activity of novel pyrimidinone containing thiazolidinedione derivatives

Madhavan, G. R., Chakrabarti, R., Vikramadithyan, R. K., Mamidi, R. N. V. S., Balraju, V., Rajesh, B. M., Misra, P., Kumar, S., Lohray, B. B., Lohray, V. B., et al. (2002) · Bioorganic & Medicinal Chemistry · doi:10.1016/s0968-0896(02)00107-4 · Cited by 60 · see citing works

Evaluation of in vitro aldose redutase inhibitory activity of 5-arylidene-2,4-thiazolidinediones

Maccari, R., Ottanà, R., Ciurleo, R., et al. (2007) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2007.04.109 · Cited by 59 · see citing works

Thiazolidinediones and the liver in humans

Yki‐Järvinen, H. (2009) · Current Opinion in Lipidology · doi:10.1097/mol.0b013e3283321d37 · Cited by 59 · see citing works

5-Aryl thiazolidine-2,4-diones: discovery of PPAR dual α/γ agonists as antidiabetic agents

Desai, R. C., Han, W., Metzger, E. J., et al. (2003) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/s0960-894x(03)00505-5 · Cited by 58 · see citing works

Discovery of 5-aryloxy-2,4-thiazolidinediones as potent GPR40 agonists

Zhou, C., Tang, C., Chang, E., et al. (2009) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2009.10.052 · Cited by 56 · see citing works

Long-term effect of rosiglitazone and/or ramipril on the incidence of diabetes

DREAM On (Diabetes Reduction Assessment with Ramipril and Rosiglitazone Medication Ongoing Follow-up) Investigators (2011) · Diabetologia · doi:10.1007/s00125-010-1985-4 · Cited by 54 · see citing works

Structural insights for the design of new PPARgamma partial agonists with high binding affinity and low transactivation activity

Guasch, L., Sala, E., Valls, C., et al. (2011) · Journal of Computer-Aided Molecular Design · doi:10.1007/s10822-011-9446-9 · Cited by 53 · see citing works

Microwave induced synthesis of the thiazolidine‐2,4‐dione motif and the efficient solvent free‐solid phase parallel syntheses of 5‐benzylidene‐thiazolidine‐2,4‐dione and 5‐benzylidene‐2‐thioxo‐thiazolidine‐4‐one compounds

Kumar, B. R. P., Nanjan, M. J., Suresh, B., et al. (2006) · Journal of Heterocyclic Chemistry · doi:10.1002/jhet.5570430413 · Cited by 53 · see citing works

Synthesis, glucose uptake activity and structure–activity relationships of some novel glitazones incorporated with glycine, aromatic and alicyclic amine moieties via two carbon acyl linker

Kumar, B. R. P., Soni, M., Kumar, S. S., Singh, K., Patil, M., Baig, R. B. N., & Adhikary, L. (2010) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2010.12.019 · Cited by 48 · see citing works

Synthesis and biological activity of some new flavonyl-2,4-thiazolidinediones

Bozdağ‐Dündar, O., Verspohl, E. J., Daş-Evcimen, N., et al. (2008) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2008.05.059 · Cited by 48 · see citing works

Thiazolidinediones/PPARγ agonists and fatty acid synthase inhibitors as an experimental combination therapy for prostate cancer

Mansour (2010) · International Journal of Oncology · doi:10.3892/ijo.2010.877 · Cited by 48 · see citing works

Novel glitazones: Design, synthesis, glucose uptake and structure–activity relationships

Kumar, B. R. P., & Nanjan, M. J. (2010) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2010.01.125 · Cited by 47 · see citing works

Chiglitazar Preferentially Regulates Gene Expression via Configuration-Restricted Binding and Phosphorylation Inhibition of PPARγ

Pan, D., Wang, W., Liu, N., Yang, Q., Zhang, K., Zhu, J.-Z., Shan, S., Li, Z., Ning, Z., Huang, L., et al. (2017) · PPAR Research · doi:10.1155/2017/4313561 · Cited by 44 · see citing works

Synthesis and biological activity of Benzoxazole containing thiazolidinedione derivatives

Jeon, R., & Park, S. (2004) · Archives of Pharmacal Research · doi:10.1007/bf02975111 · Cited by 42 · see citing works

Discovery of novel glitazones incorporated with phenylalanine and tyrosine: Synthesis, antidiabetic activity and structure–activity relationships

Kumar, B. R. P., Baig, N. B. R., Sudhir, S., V, Kar, K., Mandava, K., Pankaj, M., & Nanjan, M. J. (2012) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2012.08.002 · Cited by 40 · see citing works

Synthesis and aldose reductase inhibitory activity of some new chromonyl-2,4-thiazolidinediones

Bozdağ‐Dündar, O., Evranos, B., Daş-Evcimen, N., et al. (2008) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2008.01.004 · Cited by 39 · see citing works

5-Aryl thiazolidine-2,4-diones as selective PPARγ agonists

Koyama, H., Boueres, J. K., Han, W., et al. (2003) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/s0960-894x(03)00257-9 · Cited by 39 · see citing works

Administration of thiazolidinediones for neuroprotection in ischemic stroke: a pre‐clinical systematic review

White, A. T., & Murphy, A. N. (2010) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2010.06999.x · Cited by 36 · see citing works

Design, synthesis and docking study of 5-(substituted benzylidene)thiazolidine-2,4-dione derivatives as inhibitors of protein tyrosine phosphatase 1B

Wang, Z., Liu, Z., Lee, W., Kim, S., Yoon, G., & Cheon, S. H. (2014) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2014.05.099 · Cited by 34 · see citing works

Discovery of novel PTP1B inhibitors with antihyperglycemic activity

Liu, Z., Chai, Q., Li, Y., Shen, Q., Ma, L., Zhang, L.-N., Wang, X., Li, S., Li, J., Li, J., et al. (2010) · Acta Pharmacologica Sinica · doi:10.1038/aps.2010.81 · Cited by 32 · see citing works

Design and Biological Evaluation of Novel, Balanced Dual PPARα/γ Agonists

Grether, U., Benardeau, A. M., Benz, J., Binggeli, A., Blum, D., Hilpert, H., Kuhn, B., Märki, H. P., Meyer, M., Mohr, P., et al. (2009) · ChemMedChem · doi:10.1002/cmdc.200800425 · Cited by 29 · see citing works

Discovery of Novel Insulin Sensitizers: Promising Approaches and Targets

Chen, Y., Ma, H., Dasheng, Z., Zhao, G., Wang, L., Fu, X., & Chen, W. (2017) · PPAR Research · doi:10.1155/2017/8360919 · Cited by 29 · see citing works

Kinetics of the Absorption, Distribution, Metabolism, and Excretion of Lobeglitazone, a Novel Activator of Peroxisome Proliferator-Activated Receptor Gamma in Rats.

Lee, J.-H., Noh, C.-K., Yim, C., Jeong, Y.-S., Ahn, S.-H., Lee, W., Kim, D.-D., & Chung, S. (2015) · Journal of Pharmacy and Science · doi:10.1002/jps.24378 · Cited by 28 · see citing works

Pioglitazone: Indian perspective

Shukla, R., & Kalra, S. (2011) · Indian Journal of Endocrinology and Metabolism · doi:10.4103/2230-8210.85581 · Cited by 26 · see citing works

Synthesis and biological activity of [[(heterocycloamino)alkoxy] benzyl]-2,4-thiazolidinediones as PPARγ agonists

Jeon, R., Kim, Y. J., Cheon, Y., et al. (2006) · Archives of Pharmacal Research · doi:10.1007/bf02968589 · Cited by 26 · see citing works

Thiazolidinediones - The New Insulin Enhancers

Jha, R. (1999) · Clinical and Experimental Hypertension · doi:10.3109/10641969909068658 · Cited by 25 · see citing works

Some new thiazolyl thiazolidinedione derivatives as aldose reductase inhibitors

Bozdağ‐Dündar, O., Evcimen, N. D., Ceylan‐Ünlüsoy, M., et al. (2007) · Medicinal Chemistry Research · doi:10.1007/s00044-007-9008-9 · Cited by 24 · see citing works

The ameliorating effect of rosiglitazone on experimental nonalcoholic steatohepatitis is associated with regulating adiponectin receptor expression in rats

Liu, S., Wu, H., Zhang, Z.-Q., et al. (2010) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2010.09.082 · Cited by 22 · see citing works

Serum glucose and triglyceride lowering activity of some novel glitazones against dexamethasone-induced hyperlipidemia and insulin resistance

Nanjan, M. J., Kumar, B. R. P., Krishnamurthy, P. T., Karvekar, M. D., & Suresh, B. (2007) · Indian Journal of Pharmacology · doi:10.4103/0253-7613.39151 · Cited by 22 · see citing works

Role of the PPAR-γ System in Normal and Tumoral Pituitary Corticotropic Cells and Adrenal Cells

Mannelli, M., Cantini, G., Poli, G., et al. (2010) · Neuroendocrinology · doi:10.1159/000314312 · Cited by 21 · see citing works

Kinetics of the Absorption, Distribution, Metabolism and Excretion of Lobeglitazone, a Novel Activator of Peroxisome Proliferator-activated Receptor Gamma in Rats

이종화 (2015) · Cited by 20 · see citing works

Thiazolidinediones protect mouse pancreatic β-cells directly from cytokine-induced cytotoxicity through PPARγ-dependent mechanisms

Wang, A.-P., Li, X., Zheng, Y., Liu, B., Huang, G., Yan, X., Liu, Z., & Zhou, Z. (2010) · Acta Diabetologica · doi:10.1007/s00592-010-0239-8 · Cited by 18 · see citing works

Design, synthesis and evaluation of novel thiazolidinedione derivatives as anti-hyperglycemic and anti-hyperlipidemic agents

Shrivastava, S. K., Batham, A., Sinha, S. K., et al. (2016) · Medicinal Chemistry Research · doi:10.1007/s00044-016-1675-y · Cited by 18 · see citing works

Design, Synthesis, and Biological Evaluation of Thiazolidine‐2,4‐dione Conjugates as PPAR‐γ Agonists

Nazreen, S., Alam, M. S., Hamid, H., et al. (2015) · Archiv der Pharmazie · doi:10.1002/ardp.201400280 · Cited by 16 · see citing works

Effect of rosiglitazone on HDL metabolism in subjects with metabolic syndrome and low HDL

Millar, J. S., Ikewaki, K., Bloedon, L. T., Wolfe, M. L., Szapary, P. O., & Rader, D. J. (2010) · Journal of Lipid Research · doi:10.1194/jlr.p008136 · Cited by 15 · see citing works

Synthesis and evaluation of the hypoglycemic and hypolipidemic activity of novel 5-benzylidene-2,4-thiazolidinedione analogs in a type-2 diabetes model

Mehendale-Munj, S., Ghosh, R., & Ramaa, C. S. (2010) · Medicinal Chemistry Research · doi:10.1007/s00044-010-9359-5 · Cited by 14 · see citing works

CoMFA Study on Thiazolidine-2,4-diones for their Antihyperglycemic Activity

Nanjan, M. J., Krishnamurthy, P. T., Suresh, B., et al. (2008) · Letters in Drug Design & Discovery · doi:10.2174/157018008783928409 · Cited by 11 · see citing works

Novel glitazones: glucose uptake and cytotoxic activities, and structure–activity relationships

Kumar, B. R. P., Kumar, S., Viral, P., et al. (2011) · Medicinal Chemistry Research · doi:10.1007/s00044-011-9792-0 · Cited by 11 · see citing works

Synthesis and Evaluation of the Hypoglycemic and Hypolipidemic Activity of Novel Arylidene Thiazolidinedione Analogson a Type 2 Diabetes Model

Ahmadi, A., Khalili, M., Samavat, S., et al. (2016) · Pharmaceutical Chemistry Journal · doi:10.1007/s11094-016-1416-z · Cited by 11 · see citing works

Comparative molecular similarity indices analysis for predicting the antihyperglycemic activity of thioglitazones

Kumar, B. R. P., & Nanjan, M. J. (2009) · Medicinal Chemistry Research · doi:10.1007/s00044-009-9246-0 · Cited by 10 · see citing works

QSAR study on thiazolidine-2,4-dione derivatives for antihyperglycemic activity

Nanjan, M. J., & Kumar, B. R. P. (2008) · Indian Journal of Pharmaceutical Sciences · doi:10.4103/0250-474x.45392 · Cited by 10 · see citing works

Newer Approaches to the Discovery of Glitazones

Krishnamurthy, P. T., Chandrasekar, M., & Nanjan, M. J. (2013) · Mini-Reviews in Organic Chemistry · doi:10.2174/1570193x11310010005 · Cited by 10 · see citing works

PPARs special issue: Anchoring the present to explore the future

Desvergne, B. (2007) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2007.07.005 · Cited by 9 · see citing works

Researchers question ethics of diabetes drug trial

Mudur, G. (2002) · BMJ · doi:10.1136/bmj.325.7360.353/a · Cited by 5 · see citing works

Development of Synthetic Modulators of PPARs: Current Challenges and Future Opportunities

Pinaire, J. A., Miller, A. R., & Gregoire, F. M. (2008) · PPAR Research · doi:10.1155/2008/786359 · Cited by 4 · see citing works

Synthesis of a biotin conjugate of darglitazone, a new antidiabetic agent. A general protocol for the reversible biotinylation of ketones

Hulin, B., Lau, C. L., & Gibbs, E. M. (1993) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/s0960-894x(01)81258-0 · Cited by 4 · see citing works

Novel Glitazones with Diverse Peroxisome Proliferator Activated Receptor Modulatory Potential

Krishnamurthy, P. T., Chandrasekar, M., & Nanjan, M. J. (2014) · Current Bioactive Compounds · doi:10.2174/157340720903140119153500 · Cited by 4 · see citing works

Rigid and flexible docking studies on PPAR-γ agonists: key interactions for a better antihyperglycemic activity and in silico pharmacodynamic activity versus experimental in vivo activity

Kumar, B. R. P., Sopna, S., Verghese, J., Desai, B. J., & Nanjan, M. J. (2011) · Medicinal Chemistry Research · doi:10.1007/s00044-011-9548-x · Cited by 3 · see citing works

GFT-505

Vázquez-Carrera, M. (2012) · Drugs of the Future · doi:10.1358/dof.2012.037.08.1835977 · Cited by 2 · see citing works

Insulin Sensitizers: Emerging Therapeutics

Lohray, B. B., & Lohray, V. B. (2006) · Drug Discovery and Development · doi:10.1002/9780470085226.ch19 · Cited by 1 · see citing works

Mediterranean diet nutrients to turn the tide against insulin resistance and related diseases

Mirabelli, M., Chiefari, E., Arcidiacono, B., Corigliano, D. M., Brunetti, F. S., Maggisano, V., Russo, D., Foti, D. P., & Brunetti, A. (2020) · Nutrients · doi:10.3390/nu12041066 · Cited by 272 · see citing works

Treatment strategies against diabetes: Success so far and challenges ahead.

Khursheed, R., Singh, S. K., Wadhwa, S., Kapoor, B., Gulati, M., Kumar, R., Ramanunny, A. K., Awasthi, A., & Dua, K. (2019) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2019.172625 · Cited by 239 · see citing works

Multitarget PPARγ Agonists as Innovative Modulators of the Metabolic Syndrome

Ammazzalorso, A., Maccallini, C., Amoia, P., & Amoroso, R. (2019) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2019.04.030 · Cited by 39 · see citing works

The Role of PPARγ in Hyperglycemia-induced Deleterious Effect on ChondrocytesPreprint

Ma, C., Yang, N., Tan, Y., et al. (2020) · doi:10.21203/rs.3.rs-93188/v1

Protective properties afforded by pioglitazone against intrastriatal LPS in Sprague–Dawley rats

Hunter, R. L., Choi, D., Ross, S. A., & Bing, G. (2007) · Neuroscience Letters · doi:10.1016/j.neulet.2007.12.019 · Cited by 74 · see citing works

The PPAR-γ Agonist Pioglitazone Modulates Proliferation and Migration in HUVEC, HAOSMC and Human Arteriovenous Fistula-Derived Cells

Ciavarella, C., Motta, I., Vasuri, F., et al. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24054424 · Cited by 7 · see citing works

Pioglitazone, PPARγ Agonist, Attenuates Experimental Autoimmune Neuritis

Ramkalawan, H., Wang, Y., Ameet, H., Yang, Y., Tian, F., Zhou, W., Li, J., Yang, H., Xiao, B., & Zhang, W. (2012) · Inflammation · doi:10.1007/s10753-012-9447-4 · Cited by 16 · see citing works

THE PPAR gamma AGONIST PIOGLITAZONE UPREGULATES EAAT2 EXPRESSION IN HUMAN GLIOBLASTOMA CELLS

Ching, J., Amiridis, S., Bjorksten, A. R., et al. (2014) · Neuro-Oncology